SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosingJADE301 demonstrated high-affinity, selective IFN-β binding and greater
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect observed to be
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data
Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
